Back to Search
Start Over
Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases
- Source :
- Clinics and research in hepatology and gastroenterology. 39(6)
- Publication Year :
- 2014
-
Abstract
- Summary Background and aims We previously showed that pre-treatment serum anti-E1E2 predicted hepatitis C virus (HCV) RNA viral kinetics (VKs) and treatment outcome in patients with chronic hepatitis C receiving pegylated interferon/ribavirin (Peg-IFN/RBV) double therapy. Here, we determined whether baseline anti-E1E2 was correlated with the on-treatment VK and could predict virological outcome in treatment-experienced HCV-infected cirrhotic patients receiving protease inhibitor-based triple therapy. Methods Sera from 19 patients with HCV genotype 1 infection and compensated cirrhosis who failed to respond to a prior course of Peg-IFN/RBV were selected at time 0 before starting triple therapy with boceprevir or telaprevir. We assessed patients with sustained viral response 12 weeks after the end of triple therapy (SVR12) by analyzing VKs at weeks 4, 12, 24, 36, 48 (end of treatment) and 60. Results Patients baseline characteristics were similar to the well-defined CUPIC cohort (age, HCV subtype, baseline viremia, and treatment history). Among the 19 patients, 11 achieved an SVR12. Fifteen patients were positive for pre-treatment anti-E1E2 and all of them achieved SVR12. Moreover, anti-E1E2 and SVR12 correlated with prior response to IFN/RBV therapy (relapse, partial or null response). Conclusions Baseline anti-E1E2 could be considered as a new biomarker to predict SVR12 after triple therapy in this most difficult-to-treat population. These results warrant further validation on larger cohorts including patients receiving highly effective direct-acting antivirals to explore whether this test could help in better defining treatment duration for these very costly molecules.
- Subjects :
- Adult
Liver Cirrhosis
Male
medicine.medical_specialty
Cirrhosis
Hepatitis C virus
Population
Pilot Projects
medicine.disease_cause
Gastroenterology
Antiviral Agents
Antibodies
Telaprevir
chemistry.chemical_compound
Pegylated interferon
Predictive Value of Tests
Internal medicine
Boceprevir
Medicine
Humans
Protease inhibitor (pharmacology)
education
Aged
education.field_of_study
Hepatology
business.industry
Ribavirin
Hepatitis C, Chronic
Middle Aged
medicine.disease
Treatment Outcome
chemistry
Immunology
Drug Therapy, Combination
Female
business
Peptides
medicine.drug
Subjects
Details
- ISSN :
- 2210741X
- Volume :
- 39
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Clinics and research in hepatology and gastroenterology
- Accession number :
- edsair.doi.dedup.....81d4f5908a2dd9f45256f9376912cbe2